ProCE Banner Activity

The Future of HBV Management: Earlier Treatment and Biomarker Use

Clinical Thought

Read my take on how earlier treatment of people with chronic hepatitis B and use of different biomarkers are influencing the future of hepatitis B virus management.

Released: October 18, 2023

Share

Faculty

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Disclosure

Primary Author

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD: consultant/advisor/speaker: AbbVie, Aligos, Eiger, Galapagos, Gilead, GlaxoSmithKline, HepQuant, Mallinckrodt; researcher: Altimmune, Eiger, Gilead, Janssen, Target RWE.